Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2006;38(1):45-8.
doi: 10.1007/s11255-005-8440-3.

Prevention of pain and infective complications after transrectal prostate biopsy: a prospective study

Affiliations
Randomized Controlled Trial

Prevention of pain and infective complications after transrectal prostate biopsy: a prospective study

Ali Ferruh Akay et al. Int Urol Nephrol. 2006.

Abstract

Aim: To investigate the effects of lidocaine gel and parenteral antibiotics and povidine lavage in the treatment of pain occurring during prostate biopsy in terms of infective complications.

Patients and methods: Eighty patients with indications for prostate biopsy were randomized into two groups. One group underwent lavage with povidine iodine solution and lidocaine gel, and the other received cephtriaxon and lavage. Pain experienced by the patients was measured by visual analog scale (VAS). Blood samples were taken 15 and 60 min after the procedure, and urine culture antibiograms were taken 60 min after the procedure.

Results: The average pain score was 3.70 in Group 1 and 4.25 in Group 2; the difference between the groups was not statistically significant (P > 0.05). Likewise, no statistically significant difference between groups was found by the chi square test in either urine or blood cultures (P > 0.05).

Conclusions: Lavage with betadine prior to transrectal prostate biopsy is adequate in the prevention of infective complications; however, because lidocaine gel is not effective against pain, alternative methods for pain management need to be developed.

PubMed Disclaimer

References

    1. J Urol. 1982 Feb;127(2):255-6 - PubMed
    1. Br J Urol. 1997 Apr;79(4):608-10 - PubMed
    1. J Urol. 2001 Oct;166(4):1343-5 - PubMed
    1. Br J Urol. 1993 Apr;71(4):460-3 - PubMed
    1. Br J Urol. 1997 May;79(5):777-80 - PubMed

Publication types

MeSH terms

LinkOut - more resources